


## Certificate of Analysis

Catalog Number	BP13895
Product Name	GSK6853

## Physical and Chemical Properties

CAS No.	1910124-24-1
Chemical Formula	C <sub>22</sub> H <sub>27</sub> N <sub>5</sub> O <sub>3</sub>
Molecular Weight	409.49
Solubility	Ethanol: 81 mg/mL (197.81 mM) DMSO: 29 mg/mL
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	 <p>The chemical structure of GSK6853 is a complex molecule. It features a central benzene ring substituted with a morpholine ring, a dimethylamino group, and a benzamide derivative. The benzamide part consists of a benzene ring attached to a carbonyl group, which is further attached to an amine group. The morpholine ring is attached to the central benzene ring via its nitrogen atom. The dimethylamino group is attached to the central benzene ring via its nitrogen atom. The benzamide derivative is attached to the central benzene ring via its carbonyl group.</p>

## Product Information

Description	GSK6853 is a potent, soluble, cell-active, and highly selective inhibitor of the BRPF1 bromodomain.
Targets&IC50	BRPF1:8.1(pIC50)

In vitro	Screening GSK6853 against a panel of 48 unrelated assays reveals only off-target activities that are relatively weak compared to the BRPF1 potency. However, to minimize the chance of off-target effects , the recommended concentration is no higher than 1 $\mu$ M in cell-based assays.
In vivo	In male CD1 mouse, following IV administration (1 mg/kg), GSK6853 demonstrates a high blood clearance of 107 mL/min/kg, a moderate volume of distribution (5.5 L/kg) and a moderate terminal half-life of 1.7 h. Oral administration (PO, 3 mg/kg) achieves a moderate systemic exposure, with a Cmax of 42 ng/mL and Tmax of 1.5 h, resulting in a bioavailability of 22%. The intraperitoneal route of administration (IP, 3 mg/kg) reaches a Cmax of 469 ng/mL and Tmax of 0.25 h, resulting in a bioavailability of 85%. The results indicate that the IP route of administration would be suitable for dosing this molecule in potential PKPD models.

## Analytical Data

HPLC	Shows Min >99% purity
H-NMR	Consistent with structure
Stability and Solubility Advice	Information on product stability, especially in solution, has rarely been reported and in most cases we can only provide a general guideline. We recommend that once the stock solution has been prepared, it be stored in equal quantities in sealed vials and used within 1 month. Avoid repeated freezing and thawing cycles. Storage conditions for some special products should be referred to their storage details.

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022